Technical Analysis for NK - NantKwest, Inc.

Grade Last Price % Change Price Change
grade F 1.2 -4.00% -0.05
NK closed down 4.0 percent on Monday, October 14, 2019, on 81 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. It ran into resistance at its 50 day moving average.

Earnings due: Nov 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NK trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Fell Below 200 DMA Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
Bearish Engulfing Bearish -4.00%
Fell Below 50 DMA Bearish -4.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.00%
20 DMA Support Bullish -4.00%
Outside Day Range Expansion -4.00%
Shooting Star Candlestick Bearish -5.51%
Lizard Bearish Bearish Day Trade Setup -5.51%

Older signals for NK ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
NantKwest, Inc., a biotechnology company, develops immunotherapeutic agents for various clinical conditions. It is initiating a Phase II clinical trial for its activated natural killer product candidate for the treatment of virally-induced cancers, such as polyomavirus induced Merkel cell carcinoma, human Papillomavirus, induced cervical cancer, and head and neck cancer, as well as infectious diseases comprising Ebola and other viral, fungal, and bacterial infections. The company also holds right to commercialize a range of genetically modified derivatives that kills cancer and virally infected cells. In addition, it focuses on to initiate a Phase I/II clinical trials for target activated natural killer product candidate for acute myeloid leukemia and bulky hematological cancers. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in Cardiff-by-the-Sea, California.
Biotechnology Cancer Infectious Diseases Acute Myeloid Leukemia Infectious Causes Of Cancer Bacterial Infections Head And Neck Cancer Virus Human Papillomavirus Infection Carcinogenesis Cervical Cancer Ebola Merkel Cell Carcinoma Papillomavirus
Is NK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.1
52 Week Low 0.93
Average Volume 108,334
200-Day Moving Average 1.2149
50-Day Moving Average 1.2562
20-Day Moving Average 1.22
10-Day Moving Average 1.211
Average True Range 0.0963
ADX 20.18
+DI 13.6057
-DI 22.0879
Chandelier Exit (Long, 3 ATRs ) 1.1111
Chandelier Exit (Short, 3 ATRs ) 1.3289
Upper Bollinger Band 1.3632
Lower Bollinger Band 1.0768
Percent B (%b) 0.43
BandWidth 23.47541
MACD Line -0.0075
MACD Signal Line -0.0141
MACD Histogram 0.0066
Fundamentals Value
Market Cap 95.33 Million
Num Shares 79.4 Million
EPS -1.29
Price-to-Earnings (P/E) Ratio -0.93
Price-to-Sales 7227.62
Price-to-Book 1.46
PEG Ratio 2.18
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.37
Resistance 3 (R3) 1.38 1.33 1.34
Resistance 2 (R2) 1.33 1.29 1.33 1.33
Resistance 1 (R1) 1.27 1.26 1.24 1.26 1.32
Pivot Point 1.22 1.22 1.20 1.21 1.22
Support 1 (S1) 1.15 1.17 1.13 1.14 1.08
Support 2 (S2) 1.10 1.14 1.10 1.07
Support 3 (S3) 1.04 1.10 1.06
Support 4 (S4) 1.03